Abstract
Acquired immunodeficiency syndrome (AIDS), an infectious disease which is difficult to be cured, is regularly and effectively treated with anti-retroviral therapy in clinic. When considering about the defects of antiretroviral therapy (ART), patients need a new way to cure AIDS. With the development of genetic engineering technology and humanized mouse models, a new way has been found to achieve a “functional cure” for AIDS. One/some specific gene(s), such as CCR5 and CXCR4, can be knocked out to produce HIV-resisting cells, so as to achieve the purpose of curing AIDS. To find a safe and effective therapy for AIDS, treatment strategy and technical scheme should be improved and optimized in many aspects. Moreover, different stages of works have been done in laboratory and in clinic based on this gene mutation strategy. However, a great deal of challenge has emerged while great progress has been made. Safety considerations and effectiveness of gene modified stem cell in clinic are major obstacles of the application of this strategy.
Keywords: CCR5/CXCR4, functional cure, gene mutation, gene therapy, HIV/AIDS, HSCT.
Current Stem Cell Research & Therapy
Title:The Challenge of a “Functional Cure” for AIDS by Gene Modified HSCT Therapy
Volume: 10 Issue: 6
Author(s): Lei Xu, Hu Chen and Bin Zhang
Affiliation:
Keywords: CCR5/CXCR4, functional cure, gene mutation, gene therapy, HIV/AIDS, HSCT.
Abstract: Acquired immunodeficiency syndrome (AIDS), an infectious disease which is difficult to be cured, is regularly and effectively treated with anti-retroviral therapy in clinic. When considering about the defects of antiretroviral therapy (ART), patients need a new way to cure AIDS. With the development of genetic engineering technology and humanized mouse models, a new way has been found to achieve a “functional cure” for AIDS. One/some specific gene(s), such as CCR5 and CXCR4, can be knocked out to produce HIV-resisting cells, so as to achieve the purpose of curing AIDS. To find a safe and effective therapy for AIDS, treatment strategy and technical scheme should be improved and optimized in many aspects. Moreover, different stages of works have been done in laboratory and in clinic based on this gene mutation strategy. However, a great deal of challenge has emerged while great progress has been made. Safety considerations and effectiveness of gene modified stem cell in clinic are major obstacles of the application of this strategy.
Export Options
About this article
Cite this article as:
Xu Lei, Chen Hu and Zhang Bin, The Challenge of a “Functional Cure” for AIDS by Gene Modified HSCT Therapy, Current Stem Cell Research & Therapy 2015; 10 (6) . https://dx.doi.org/10.2174/1574888X10666150519094026
DOI https://dx.doi.org/10.2174/1574888X10666150519094026 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2)
Current Pharmaceutical Design Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Applications of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Pulmonary Disease
Current Respiratory Medicine Reviews Rituxan® Immunotherapy and Zevalin® Radioimmunotherapy in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Pharmacogenomics of Human ABC Transporters: Detection of Clinically Important SNPs by SmartAmp2 Method
Current Pharmaceutical Biotechnology Trailing TRAIL Resistance in Human Breast Adenocarcinoma Cells with Trichostatin A and Zebularine
Anti-Cancer Agents in Medicinal Chemistry Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design An Overwiev of ORF Virus Infection in Humans and Animals
Recent Patents on Anti-Infective Drug Discovery Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies